Lundbeck is a global pharmaceutical company highly committed to improving the quality of life of people living with psychiatric and neurological disorders, and the only global pharmaceutical company solely focused on this area. The company’s products and development projects are primarily targeted at depression, schizophrenia, Parkinson’s disease and Alzheimer’s disease.
According to the World Health Organization, WHO, more than 700 million people live with psychiatric and neurological disorders globally. These are serious and life-threatening diseases that affect the quality of life of the patients as well as of their relatives. As these diseases also involve major socio-economic costs, it is imperative for the general society that new and innovative pharmaceuticals are developed. Over the past 70 years, new pharmaceuticals have revolutionised the treatment options, but there remains a large unmet need for new and innovative therapeutics.
Our sustainability framework aims to ensure that our business activities are conducted in a way that mitigates the related significant risks and that supports the UN Global Compact Principles and the relevant UN Sustainable Development Goals.